With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making.

We serve over 300 pharmaceutical, biotech and medical device clients, helping them develop the right drugs and devices for today’s market and optimize them once in market. In 2023, the company worked on 75% of all new drug launches and provides ongoing, in-depth, high value thought leadership that helps shape the industry.

With a diverse staff of over 1,200 employees and 11 global offices across the U.S., Europe and Asia, Trinity continues to grow both organically and through acquisitions. These acquisitions included BluePrint Research Group, CBPartners, TGaS Advisors, Bell Canyon and D Cube Analytics, the latter of which dramatically leap-frogged Trinity to the leading provider of go-to-market analytics and AI to biopharma companies. Trinity has also entered into a transformative partnership with Bain & Company that has strategically advanced Trinity’s mission to revolutionize the pharmaceutical commercial model.

Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits.